Hyperscale Data shifts to bitcoin-only treasury strategy
Investing.com - Mizuho maintained its Outperform rating and $2.00 price target on Senseonics Holdings (NYSE:SENS), currently trading at $0.46, following the company’s announcement of a strategic distribution change. According to InvestingPro data, analysts’ targets range from $1.00 to $2.00, suggesting significant upside potential.
Senseonics revealed it has executed a mutual Memorandum of Understanding (MOU) to transition all E365 and future product commercialization and distribution rights away from Ascensia Diabetes Care, a member of PHC Group, back to Senseonics itself.
The original agreement had granted Ascensia worldwide distribution rights for current and future Eversense products in exchange for a portion of net revenues ranging from mid-teens to mid-forties percentages based on global revenue milestones.
The agreement included termination provisions if Ascensia failed to meet pre-determined investment levels and global sales targets, though Mizuho confirmed the MOU was not initiated as a push for termination by either party.
Mizuho views the pending separation as a positive development, noting it was driven by "strong initial E365 adoption which accelerated through August," reinforcing the firm’s Outperform stance on the stock. InvestingPro analysis reveals the company holds more cash than debt and maintains strong liquidity. Get deeper insights and access to additional ProTips with an InvestingPro subscription.
In other recent news, Senseonics Holdings reported its second-quarter 2025 financial results, with net revenue reaching $6.6 million, surpassing the forecasted $6.01 million. Despite this revenue beat, the company’s earnings per share (EPS) met expectations with a loss of $0.02. Barclays initiated coverage on Senseonics with an Overweight rating, setting a price target of $1.50. The investment bank highlighted the potential of the company’s Eversense 365 implantable continuous glucose monitoring (CGM) system, which may create a new category in the global CGM market. Meanwhile, Raymond James reiterated its Underperform rating on Senseonics, with no change to its price target. The company maintained its full-year 2025 revenue guidance, despite the revenue surpassing Raymond James’ estimates. These developments reflect ongoing interest and varied perspectives from analysts regarding Senseonics’ market potential and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.